A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Melinda A PruisMatthew G KrebsRuth PlummerFilip Yves Francine De VosEric AngevinHans PrenenMartin D ForsterGlen ClackAnnegret Van der AaMarc TjwaEllen JansenTimothy PereraMartijn Paul LolkemaPublished in: The oncologist (2023)
OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients.
Keyphrases